Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbic acid and esketamine for postoperative mental state after painless abortion
ChiCTR2400094712Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ascorbic acid and esketamine in perioperative psychiatric disorder (PPD), major depressive disorder (MDD), anxiety disorder and 1 more (6 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Incidence of post-abortion depression assessed by Edinburgh Postnatal Depression Scale. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ascorbic acidesketamine
03
Conditions
perioperative psychiatric disorder (PPD)major depressive disorder (MDD)anxiety disorderInsomnia
Beyond the preview
Go deeper on ChiCTR2400094712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094712.